| CTRI Number |
CTRI/2023/07/055549 [Registered on: 24/07/2023] Trial Registered Prospectively |
| Last Modified On: |
17/05/2025 |
| Post Graduate Thesis |
Yes |
| Type of Trial |
Interventional |
|
Type of Study
|
Drug |
| Study Design |
Randomized, Parallel Group, Active Controlled Trial |
|
Public Title of Study
|
Comparison between an injection treatment of botulinum toxin A and an oral tablet glycopyrrolate in patients of cerebral dysfunction with complaints ofexcessive salivation |
|
Scientific Title of Study
|
A comparative study on efficacy between ultrasound-guided botulinum toxin type a injection to salivary glands and oral glycopyrrolate therapy for management of sialorrhea in cerebral palsy |
| Trial Acronym |
Nil |
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| NIL |
NIL |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
Indrajit De |
| Designation |
Post Graduate Traniee |
| Affiliation |
Institute of Postgraduate Medical Education and Research |
| Address |
Department of Physical Medicine and Rehabilitation
Institute of Postgraduate Medical Education and Research
244 AJC Bose Road, Kolkata- 700020
Kolkata WEST BENGAL 700020 India |
| Phone |
8145549644 |
| Fax |
|
| Email |
indrajitde.id@gmail.com |
|
Details of Contact Person Scientific Query
|
| Name |
Firdaus Kamal |
| Designation |
Professor |
| Affiliation |
Institute of Postgraduate Medical Education and Research |
| Address |
Department of Physical Medicine and Rehabilitation Institute of Postgraduate Medical Education and Research
244 AJC Bose Road, Kolkata
Kolkata WEST BENGAL 700020 India |
| Phone |
9830219554 |
| Fax |
|
| Email |
kamal.firdaus.kamal@gmail.com |
|
Details of Contact Person Public Query
|
| Name |
Firdaus Kamal |
| Designation |
Professor |
| Affiliation |
Institute of Postgraduate Medical Education and Research |
| Address |
Department of Physical Medicine and Rehabilitation Institute of Postgraduate Medical Education and Research
244 AJC Bose Road, Kolkata
WEST BENGAL 700020 India |
| Phone |
9830219554 |
| Fax |
|
| Email |
kamal.firdaus.kamal@gmail.com |
|
|
Source of Monetary or Material Support
|
| Institute of Postgraduate Medical Education and Research |
|
|
Primary Sponsor
|
| Name |
Institute of Postgraduate Medical Education and Research |
| Address |
Institute of Post Graduate Medical Education and Research
244 AJC Bose Road, Kolkata-700020 |
| Type of Sponsor |
Government medical college |
|
|
Details of Secondary Sponsor
|
|
|
Countries of Recruitment
|
India |
|
Sites of Study
|
| No of Sites = 1 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| Dr Indrajit De |
Institute of Post Graduate Medical Education and Research |
Department of Physical medicine and Rehabilitation OPD and IPD
Institute of Postgraduate Medical Education and Research
244 AJC Bose Road, Kolkata- 700020 Kolkata WEST BENGAL |
8145549644
indrajitde.id@gmail.com |
|
|
Details of Ethics Committee
|
| No of Ethics Committees= 1 |
| Name of Committee |
Approval Status |
| IPGME and R Research Oversight Committee |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Patients |
(1) ICD-10 Condition: G80||Cerebral palsy, |
|
|
Intervention / Comparator Agent
|
| Type |
Name |
Details |
| Intervention |
Botulinum Toxin Type A |
botulinum toxin type A injections under USG guidance by maintaining proper aseptic condition using 25/27 G needle with max 100 units of inj botulinum toxin type A reconstitute with 2 ml of NS for a single setting with each gland 1U/kg/gland dose with a depth of needle 0.5 to 1 cm. Procedure will be done under local anesthesia and in fasting condition. patient will be followed up after 2 hours of procedure (only for observation), then at 2 weeks, 4 weeks and 12 weeks at outpatient day basis |
| Comparator Agent |
Oral Glycopyrrolate |
glycopyrrolate therapy will be started with a minimum dose of 0.10 mg/kg twice daily dose, after starting medication assessment will be done at 2 weeks,1 month and 3 months interval |
|
|
Inclusion Criteria
|
| Age From |
4.00 Year(s) |
| Age To |
12.00 Year(s) |
| Gender |
Both |
| Details |
1.Confirmed case of cerebral palsy.
2.Drooling Severity (DS) Scale score 3 or more.
3.Drooling Frequency (DF) scale score 3 or more.
4.Consent from the guardian or relative |
|
| ExclusionCriteria |
| Details |
1.Local site infection. 2.Allergy to botulinum toxin type A or oral Glycopyrrolate.
3.H/O severe Dysphagia.
4.H/O surgery done for controlling of sialorrhea. Or any h/o of salivary gland excision surgery mainly parotid and submandibular. 5.Abnormal coagulation profile. 6.Patients suffering from unstable cardio vascular or serious respiratory diseases. |
|
|
Method of Generating Random Sequence
|
Stratified randomization |
|
Method of Concealment
|
Not Applicable |
|
Blinding/Masking
|
Open Label |
|
Primary Outcome
|
| Outcome |
TimePoints |
| Ultrasound guided botulinum toxin type A injection to salivary glands (b/l parotid & submandibular) versus otal glycopyrrolate in sialorrhea in cerebral palsy patients will be compared for efficacy |
1 year |
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
| Improvement of quality of life physically & psychologically following application of botulinum toxin type A injection over oral glycopyrrolate therapy will be compared. |
1 year |
|
|
Target Sample Size
|
Total Sample Size="44" Sample Size from India="44"
Final Enrollment numbers achieved (Total)= "44"
Final Enrollment numbers achieved (India)="44" |
|
Phase of Trial
|
Phase 1/ Phase 2 |
|
Date of First Enrollment (India)
|
31/07/2023 |
| Date of Study Completion (India) |
13/11/2024 |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Date Missing |
|
Estimated Duration of Trial
|
Years="1" Months="6" Days="0" |
Recruitment Status of Trial (Global)
Modification(s)
|
Not Yet Recruiting |
| Recruitment Status of Trial (India) |
Completed |
Publication Details
Modification(s)
|
N/A |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
Brief Summary
Modification(s)
|
Objective of proposed research: To observe separate efficacy between ultrasound guided botulinum toxin type A injection to salivary glands (parotid and submandibular) and oral Glycopyrrolate therapy for management of sialorrhea in children with cerebral palsy and compare between them. Background of present study: It is noted in our regular practice that sialorrhea is one of the common presentations in children with cerebral palsy. Around (15-20%) of physically disabled children are affected by Cerebral Palsy (CP). In India, the estimated incidence is around 3/1000 live births. CP is associated with many comorbidities including sialorrhea. The most common cause of sialorrhea in children is cerebral palsy with an incidence rate of approximate (10 to 58%). There are a lot of approaches to manage sialorrhea including behavioural interventions, oral and topical medications, radiation therapy and surgery. However, there is currently no satisfactory solution. The use of oral anticholinergic medication like glycopyrrolate is also limited because of several side effects although it has faster onset of action. As sialorrhea is very much difficult to control with this already existing therapy including oral pharmacological therapy. Hence the need for intervention rises. The application of ultrasound guided botulinum toxin type A injection to salivary glands (parotid and submandibular) has been shown to be a safe and effective option to treat children with moderate and severe sialorrhea, improving quality of life physically and psychologically. But the efficacy of botulinum toxin injection over oral glycopyrrolate is not properly established and very few literatures have been found. with. So, in this study we will aim to clarify whether Botulinum toxin type A injection has additional value over oral glycopyrrolate therapy for management of sialorrhea in cerebral palsy patients. 6. Methodology: a. Study design: Parallel group, Open label, Randomized Controlled Trial. b. Study duration: 18 months. c. Place of study: Department of Physical Medicine & Rehabilitation (PM&R), IPGME&R and SSKM Hospital, Kolkata. d. Study Population: Patients attending OPDs and admitted in IPDs of Department of PM&R fulfilling inclusion and exclusion criteria. e. Sample Size: Total 44(22 in each group). 7. Expected outcome: Application of ultrasound guided botulinum toxin type A injection to salivary glands (b/l parotid and submandibular) is a better and safe alternative method for management of sialorrhea over existing methods of therapy including oral glycopyrrolate in cerebral palsy patients. |